Clinical Trial Search

Primary: Change in Clinician-Administered PTSD Scale (CAPS-IV) From Baseline to Primary Endpoint — -11.4; -58.3; -44.3 score on a scale

Primary: Change From Baseline in Modified Rodnan Skin Score to Week 24 — -2.45; -4.76 score on a scale — p=0.0291

Primary: Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16 — 62.6; 72.4 percentage of participants…

Primary: Least Squares Mean Contact Lens Corrected Distance Visual Acuity (CLCDVA) in Each Eye (CLL949-C018 + CLL949-C009) — -0.06; -0.05 logMAR

Primary: Percentage of Participant Eyes With an Uncorrected Visual Acuity of 20/20 or Better — 94; 83 percentage of participant eyes

Primary: Number of Participants With Treatment Emergent Adverse Events — 0; 0 Participants

Primary: Hematocrit Level — 51.5; 52.6 % of blood composed of red blood cells — p=0.572

Primary: Number of Participants Who Experienced Adverse Events (AEs) or Serious AE — 234; 1532; 270; 315 participants

Primary: Number of Participants With One Grade 1 Adverse Event, More Than One Grade 1 Adverse Event, and One Grade 2 Adverse Event — 4; 2; 4 Participants

Primary: Overall Response Rate (ORR) — 45.16 percentage of participants

Primary: Distance Visual Acuity (VA) With Study Lenses - Completed Eyes — -0.06; -0.06; -0.06; -0.05 logMAR

Primary: Best Corrected Distance Visual Acuity — 308 Participants

Primary: Opioid Utilization — 54.79; 30.38 Morphine Milligram Equivalents (MME)

Primary: Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score up to End of Study (EOS) (Week 103) — 0.17 Z-score

Primary: Insulin Sensitivity — 8.559; 3.425; 3.756; 2.985 x10-4/min-1/mIU/mL